Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis

被引:37
|
作者
Fan, Mengying [1 ]
Lin, Yao [1 ]
Pan, Jianhong [1 ]
Yan, Wanpu [1 ]
Dai, Liang [1 ]
Shen, Luyan [1 ]
Chen, Keneng [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Thorac Surg 1,Key Lab Carcinogenesis & Trans, Beijing 100142, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Esophageal cancer; induction chemoradiotherapy; induction chemotherapy; overall survival; CHEMORADIATION; STRATEGIES; MORTALITY;
D O I
10.1111/1759-7714.12299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe efficacy of surgery alone for patients with locally advanced esophageal cancer (EC) is still unsatisfactory. Presently, induction therapy followed by surgery is the standard treatment. Preoperative chemotherapy (CT) and chemoradiation (CRT) are proven effective induction therapies; however, few sample studies have addressed these treatments, thus, their superiority remains uncertain. We performed a systemic review and meta analysis to test the hypothesis that induction CRT prior to surgery could improve survival compared with induction CT alone. MethodsA comprehensive search of PubMed and the Ovid database for relevant studies comparing EC patients undergoing resection after treatment with induction CT alone or induction CRT was conducted. Hazard ratios (HR) and 95% confidence intervals (95% CI) were extracted from these studies to provide pooled estimates of the effect of induction therapy on overall survival. ResultsFive studies met the criteria for analysis. Statistical analysis demonstrated a survival benefit of induction CRT compared with induction CT alone (HR0.73, 95% CI 0.61-0.89; P = 0.002). Further analysis showed that induction CRT perioperative mortality and complication rates were higher than for induction CT alone (HR 2.96, 95% CI 1.38-6.37; HR1.6, 95% CI 1.30-1.98; P = 0.01, respectively). ConclusionsPublished evidence comparing the different efficacies of induction CT and induction CRT is sparse, with few samples of adenocarcinoma. This analysis supports the view that, compared with induction CT, induction CRT could achieve a long-term survival benefit in EC patients.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 50 条
  • [41] Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma
    Yang, Guozhen
    Yue, Haodong
    Zhang, Xiaomin
    Zeng, Chufeng
    Tan, Linyu
    Zhang, Xu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [42] Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis
    Ma, Hai-Feng
    Lv, Guo-Xiao
    Cai, Zhong-Fang
    Zhang, Da-Hai
    ONCOTARGETS AND THERAPY, 2018, 11 : 3441 - 3447
  • [43] The use of neoadjuvant chemoradiotherapy for resectable esophageal cancer
    Chidel, M
    Rice, TW
    Kupelian, PA
    Adelstein, D
    Becker, M
    RADIOLOGY, 1997, 205 : 1082 - 1082
  • [44] Neoadjuvant chemoradiotherapy for esophageal carcinoma
    Zhang, X
    Watson, DI
    Jamieson, GG
    Bessell, JR
    Devitt, PG
    DISEASES OF THE ESOPHAGUS, 2005, 18 (02) : 104 - 108
  • [45] Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Yu, Yong-kui
    Meng, Fan-Yu
    Wei, Xiu-feng
    Chen, Xian-kai
    Li, Hao-miao
    Liu, Qi
    Li, Can-jun
    Xie, Hou-nai
    Xu, Lei
    Zhang, Rui-xiang
    Xing, Wenqun
    Li, Yin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (02):
  • [46] Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis
    Csontos, Armand
    Fazekas, Aliz
    Szako, Lajos
    Farkas, Nelli
    Papp, Csenge
    Ferenczi, Szilard
    Bellyei, Szabolcs
    Hegyi, Peter
    Papp, Andras
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (11) : 1621 - 1635
  • [47] Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis
    Wang, Peiyuan
    Chen, Yujie
    Lei, Mengxia
    He, Hao
    Zhang, Derong
    Lin, Junpeng
    Lin, Hui
    Wei, Wenwei
    Chen, Peng
    Zhuang, Fengnian
    Chen, Weijie
    Zhou, Hang
    Gao, Pengqiang
    Liu, Shuoyan
    Wang, Feng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (10)
  • [48] Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma
    Okamura, A.
    Watanabe, M.
    Mine, S.
    Kurogochi, T.
    Yamashita, K.
    Hayami, M.
    Imamura, Y.
    Ogura, M.
    Ichimura, T.
    Takahari, D.
    Chin, K.
    DISEASES OF THE ESOPHAGUS, 2017, 30 (09): : 1 - 8
  • [49] Neoadjuvant and Adjuvant Treatments for Resectable Esophageal Cancer: A Network Meta-Analysis
    Yuan, M.
    Bao, Y.
    Ma, Z.
    Wang, Y.
    Men, Y.
    Kang, J.
    Sun, X.
    Zhao, M.
    Yang, X.
    Sun, S.
    Hui, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E651 - E652
  • [50] Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer
    Zhu, Yusen
    Liu, Min
    Yun, Xiaojing
    Wang, Dongmei
    Bai, Yuhuan
    Zhang, Guizhi
    Ji, Bei
    Jing, Changchun
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 657 - 663